Compare SCNX & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCNX | ONMD |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 38.8M |
| IPO Year | 2019 | 2021 |
| Metric | SCNX | ONMD |
|---|---|---|
| Price | $0.28 | $3.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 609.4K | 267.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,831,778.00 | $1,359,000.00 |
| Revenue This Year | $1,097.38 | N/A |
| Revenue Next Year | $239.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 30.72 | ★ 111.35 |
| 52 Week Low | $0.24 | $0.49 |
| 52 Week High | $2.60 | $4.22 |
| Indicator | SCNX | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 23.28 | 47.37 |
| Support Level | $0.24 | $0.58 |
| Resistance Level | $0.43 | $0.83 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 7.47 | 15.79 |
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.